GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are effective pharmacotherapies for obesity, producing significant weight loss and cardiovascular benefits.

The second-generation medications... are coming closer to bariatric surgery average weight losses with 16%–17% and 19%–20% respectively... The SELECT trial solidifies that the use of semaglutide in those with overweight or obesity should take its place alongside other standard evidence-based practices such as pharmacologic treatment of HTN, diabetes, and dyslipidemia for secondary atherosclerotic cardiovascular disease prevention.